"Active Dendrobium superfine powder" technology patented
Release time:
2020-08-14
"Active Dendrobium officinale Ultrafine Powder" Technology Obtained Patent
News Peak Health Technology Company's Technical Achievement "Preparation Method of Active Dendrobium officinale Ultrafine Powder" Recently Obtained Invention Patent No. ZL 201510242263.8 , Valid 20 Years. Compared with the traditional method, the Dendrobium officinale powder prepared by this technology fully retains the original drug activity, and the bioavailability is doubled.
Dendrobium officinale is known as "plant gold". It has the effects of nourishing body fluid and stomach, nourishing yin and clearing heat, moistening lung and kidney, improving eyesight and strengthening waist. The common traditional Chinese medicine maple bucket on the market is made of fresh Dendrobium officinale while being heated, twisted into a spiral shape or spring shape, and dried and processed. People usually smash the iron maple bucket into fine powder and take it together with American ginseng fine powder. However, conventional drying will cause the active ingredients and effective ingredients of Dendrobium officinale to be damaged, and the taste, color and appearance will change. In addition, the crushing time is relatively long, and some materials are heated relatively high during crushing, which further leads to the decrease of its efficacy, and the rehydration of the processed fine powder is also relatively poor, thus affecting the effect. The patent achievement of Spike Health "a preparation method of active Dendrobium officinale superfine powder" effectively solves the above-mentioned drawbacks. In this method, the vacuum freeze-dried Dendrobium candidum is then crushed by a low-temperature ultra-high-speed airflow crushing process, and the crushing temperature is controlled at 20 ℃ and below, so as to avoid the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the crushing process of Dendrobium candidum; its fineness can reach above 95% and the particle size of is below 20 μ m , which increases the particle fineness of traditional Dendrobium officinale powder by 10-20 times. Since the particle fineness of Dendrobium officinale powder reaches 10-15 μ m , it can be directly absorbed through human mucosa. The increase of particle surface area makes the effective ingredients easy to dissolve and absorb, and its bioavailability is doubled, which can reach the absorption degree of Dendrobium officinale net extract and strengthen its physiological activity. At the same time, because the superfine powder of Dendrobium officinale uses a physical method, the temperature is effectively controlled, so that the activity of Dendrobium officinale is completely retained, and the various effective ingredients of Dendrobium officinale are completely retained without any damage, achieving less dosage and quick effect. Better than the ordinary commonly used only dozens of heat dry Dendrobium powder.
At the same time, in terms of production, this method directly freezes fresh Dendrobium candidum and then carries out low-temperature airflow crushing to prepare active Dendrobium candidum superfine powder. The color and quality are basically the same as those of fresh products. The product has excellent water rehydration, can quickly absorb water and recover, can retain the active ingredients in Dendrobium candidum to the greatest extent, give full play to the drug effect, and shorten production cycle, the energy consumption and cost of freeze-drying are reduced. When the active dendrobium superfine powder made by this method is prepared into capsules or tablets or buccal tablets according to conventional methods, it has the characteristics of high activity, high content, low dosage and easy absorption, which improves its economic and use value. (Lu Guosheng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page